Conexeu Sciences, Inc. (CNXU)
4.96
-0.34
(-6.42%)
USD |
NASDAQ |
Sep 18, 16:00
4.89
-0.07
(-1.41%)
After-Hours: 20:00
Conexeu Sciences Enterprise Value : 133.75M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 133.75M |
| September 17, 2026 | 143.07M |
| September 16, 2026 | 124.44M |
| September 15, 2026 | 119.78M |
| September 14, 2026 | 134.85M |
| September 11, 2026 | 120.05M |
| September 10, 2026 | 114.30M |
| September 09, 2026 | 120.05M |
| September 08, 2026 | 126.08M |
| September 04, 2026 | 134.03M |
| September 03, 2026 | 142.25M |
| September 02, 2026 | 150.19M |
| September 01, 2026 | 158.68M |
| August 31, 2026 | 194.44M |
| August 28, 2026 | 191.56M |
| August 27, 2026 | 190.74M |
| August 26, 2026 | 188.96M |
| August 25, 2026 | 204.71M |
| August 24, 2026 | 211.84M |
| August 21, 2026 | 241.42M |
| August 20, 2026 | 256.22M |
| August 19, 2026 | 243.34M |
| August 18, 2026 | 271.56M |
| August 17, 2026 | 265.81M |
| August 14, 2026 | 241.70M |
| Date | Value |
|---|---|
| August 13, 2026 | 216.22M |
| August 12, 2026 | 198.14M |
| August 11, 2026 | 201.70M |
| August 10, 2026 | 197.04M |
| August 07, 2026 | 218.96M |
| August 06, 2026 | 229.92M |
| August 05, 2026 | 244.16M |
| August 04, 2026 | 246.63M |
| August 03, 2026 | 210.47M |
| July 31, 2026 | 225.53M |
| July 30, 2026 | 228.97M |
| July 29, 2026 | 203.82M |
| July 28, 2026 | 201.15M |
| July 27, 2026 | 198.20M |
| July 24, 2026 | 222.02M |
| July 23, 2026 | 237.54M |
| July 22, 2026 | 242.62M |
| July 21, 2026 | 250.92M |
| July 20, 2026 | 230.31M |
| July 17, 2026 | 255.73M |
| July 16, 2026 | 273.93M |
| July 15, 2026 | 291.86M |
| July 14, 2026 | 246.90M |
| July 13, 2026 | 269.38M |
| July 10, 2026 | 265.63M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 530.74B |
| Vericel Corp. | 1.980B |
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.726M |
| Total Expenses (Quarterly) | 7.726M |
| EPS Diluted (Quarterly) | -0.282 |
| Earnings Yield | -9.23% |